Wound healing is an essential physiological process in which tissue repair and regeneration occur after injury. The lack of several factors for wound healing such as growth factors and extra-cellular matrix (ECM) has been observed in hard-to-heal wounds. Drugs developed from growth factors failed to provide expected outcome; therefore, ECM proteins approach is emerging as a promising alteration. Human neonatal dermal fibroblasts were used for in vitro experiments. Either pure liposomes, fibronectin or fibronectin coated on liposomes were delivered to the cells. WST-1 cell proliferation assay and fluorescence live-cell imaging were performed to evaluate cell growth and migration in each group. Mouse model of ulcerative colitis induced by acetic acid was used for in vivo experiments. HE staining of the colon tissues and measurement of inflammatory cytokines level were performed in our study. We found a significantly faster growth in the cells in which liposomes coated by fibronectin (FN) were delivered. Moreover, in in-vitro scratch assay, this group has remarkably shorter recovery time compared to the control group. In vivo data confirmed that the mice treated with FN-coated liposomes had less tissue damage than other groups after 10 days of treatment. Our results revealed that fibronectin, when coated to liposomes prior to delivery to cells, can have significantly higher effect in wound healing than when delivered with no carrier. This enables the ability to develop a wound healing material using our SUV-based ECM delivery system. The underlying mechanism of the wound healing process facilitated by this system remains to be revealed in further studies.